The MSK Breast MRI Lab is dedicated to research in breast magnetic resonance imaging (MRI). Our group includes clinical investigators and scientists working in computer science, engineering, and physics as well as national and international research fellows. Research activities are interdisciplinary and interactive between science and medicine.
Elizabeth Morris, MD, FACR, FSBI, FISMRM
Chief, Breast Imaging Service; Larry Norton Endowed Chair; Member, Memorial Sloan Kettering Cancer Center; Professor of Radiology, Weill Cornell Medical College
Research FocusRadiologist Elizabeth Morris uses MRI imaging data and genomics data to predict diagnosis, response to therapy, and outcomes for people with breast cancer.
- Sutton EJ, Oh JH, Dashevsky BZ, Veeraraghavan H, Apte AP, Thakur SB, Deasy JO, Morris EA. Breast cancer subtype intertumor heterogeneity: MRI-based features predict results of a genomic assay. J Magn Reson Imaging. 2015 Nov;42(5):1398-406. doi: 10.1002/jmri.24890. PubMed Central PMCID: PMC4784421.
- Pinker K, Moy L, Sutton EJ, Mann RM, Weber M, Thakur SB, Jochelson MS, Bago-Horvath Z, Morris EA, Baltzer PA, Helbich TH. Diffusion-Weighted Imaging With Apparent Diffusion Coefficient Mapping for Breast Cancer Detection as a Stand-Alone Parameter: Comparison With Dynamic Contrast-Enhanced and Multiparametric Magnetic Resonance Imaging. Invest Radiol. 2018 Apr 3. doi: 10.1097/RLI.0000000000000465.
- Elizabeth Morris - Breast Cancer Research Foundation Award: Support for the 2017 International Working Group Risk Assessment and Strategies for Screening and Prevention Meeting
- Elizabeth Morris – Susan G Komen Breast Cancer Foundation: Komen Leadership Grant Award
- Katja Pinker-Domenig - European Union’s Horizon 2020 Research and Innovation Programme Award: Digital Hybrid Breast PET/MRI for Enhanced Diagnosis of Breast Cancer / Hybrid Imaging for Breast Cancer
- Elizabeth Sutton - Radiological Society of North America – Research Scholar Award: Percutaneous Breast MRI Biopsy as an Alternative to Surgery In Diagnosing A Complete Pathologic Response Post Neoadjuvant Chemotherapy